DelveInsight’s, “Vulvar Cancer Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Vulvar Cancer pipeline landscape. It covers the Vulvar Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vulvar Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Vulvar Cancer Pipeline Outlook Report
Key Takeaways from the Vulvar Cancer Pipeline Report
- In February 2025, UNICANCER conducted an interventional study to evaluate the efficacy of immunotherapy (pembrolizumab) in combination with targeted therapy (vorinostat) in patients with recurrent and/or metastatic squamous cell carcinoma, including head and neck, lung, cervix, anus, vulva cancer.
- DelveInsight’s Vulvar Cancer pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Vulvar Cancer treatment.
- The leading Vulvar Cancer Companies such as TScan Therapeutics, Inc., Transgene, Marengo Therapeutics, Inc., SCG Cell Therapy Pte. Ltd., HRYZ Biotech Co., GI Innovation, Inc. and others.
- Promising Vulvar Cancer Therapies such as V503, Cisplatin, Pembrolizumab, HPV Vaccine, Cardunolizumab and others.
Learn how leading Vulvar Cancer Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Vulvar Cancer Clinical Trials Assessment
Vulvar Cancer Emerging Drugs
- TG4001: Transgene
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens. The company has selected typical papillomavirus sequences that code for these antigens and have incorporated them into the DNA of a viral vector (MVA). It has also introduced a gene that codes for a molecule (interleukin 2, IL-2) that will stimulate the immune system at the injection site. TG4001 triggers a specific immune response that supports the recognition and destruction of cancer cells carrying the HPV viral antigens. This approach enables the body to destroy the tumours. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Vulvar Cancer.
- GI-101: GI Innovation, Inc.
GI-101 is a novel immunotherapeutic agent developed by GI Innovation, Inc., designed as a bispecific fusion protein that combines CD80 and an interleukin-2 (IL-2) variant. This innovative drug aims to enhance anti-tumor immunity by targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and preferentially binding to the IL-2 receptor beta subunit (IL-2Rβ). Preclinical studies have demonstrated that GI-101 exhibits strong anti-tumor efficacy, stimulating the proliferation of CD8+ T cells and natural killer (NK) cells while minimizing the expansion of regulatory T cells, which are often implicated in immune suppression within the tumor microenvironment. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Vulvar Cancer.
- HRYZ-T101: HRYZ Biotech Co.
HRYZ-T101 is an innovative therapeutic agent developed by HRYZ Biotech Co., designed to target various cancers through a unique mechanism of action. It is a novel bispecific T-cell engager (BiTE) that aims to enhance the immune system’s ability to recognize and eliminate cancer cells. By simultaneously binding to CD3 on T cells and a specific tumor-associated antigen (TAA), HRYZ-T101 facilitates the activation and proliferation of T cells in the presence of tumor cells, thereby promoting targeted cytotoxicity against malignant tissues. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Vulvar Cancer.
The Vulvar Cancer Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Vulvar Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vulvar Cancer Treatment.
- Vulvar Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Vulvar Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vulvar Cancer market.
From early-stage research to late-phase Vulvar Cancer Clinical Trials, our analysis covers key Vulvar Cancer Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Vulvar Cancer Treatment Drugs
Vulvar Cancer Companies
TScan Therapeutics, Inc., Transgene, Marengo Therapeutics, Inc., SCG Cell Therapy Pte. Ltd., HRYZ Biotech Co., GI Innovation, Inc. and others
Vulvar Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Topical
- Subcutaneous
- Parenteral
Vulvar Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Stay updated with the latest Vulvar Cancer Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Vulvar Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Vulvar Cancer Pipeline Report
- Coverage- Global
- Vulvar Cancer Companies- TScan Therapeutics, Inc., Transgene, Marengo Therapeutics, Inc., SCG Cell Therapy Pte. Ltd., HRYZ Biotech Co., GI Innovation, Inc. and others.
- Vulvar Cancer Therapies- V503, Cisplatin, Pembrolizumab, HPV Vaccine, Cardunolizumab and others.
- Vulvar Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Vulvar Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Vulvar Cancer Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Vulvar Cancer Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Vulvar Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Vulvar Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- 9-valent Human Papillomavirus Recombinant Vaccine: Shanghai Bovax Biotechnology Co., Ltd.
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TG4001: Transgene
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HRYZ-T101: HRYZ Biotech Co.
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Vulvar Cancer Key Companies
- Vulvar Cancer Key Products
- Vulvar Cancer- Unmet Needs
- Vulvar Cancer- Market Drivers and Barriers
- Vulvar Cancer- Future Perspectives and Conclusion
- Vulvar Cancer Analyst Views
- Vulvar Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market